Associations - EGFR exon 19 mutation

BIOMARKER:

EGFR exon 19 mutation

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: C3 – Early Trials gefitinib Sensitive : C3
EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	cisplatin + gefitinib + docetaxel Sensitive: C3 – Early Trials cisplatin + gefitinib + docetaxel Sensitive : C3
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
EGFR exon 19 mutation EGFR exon 19 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	erlotinib Sensitive: C4 – Case Studies erlotinib Sensitive : C4